NCT06694324

First-line Treatment of Advanced/unresectable DDLPS

Liposomal Doxorubicin Hydrochloride and Apatinib in Combination with Camrelizumab for the First-line Treatment of Advanced/unresectable Dedifferentiated Liposarcoma

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 49 (estimated)
• Sponsor: Fudan University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Evaluating the efficacy and safety of liposomal doxorubicin hydrochloride and apatinib in combination with camrelizumab for the first-line treatment of advanced/unresectable dedifferentiated liposarcoma

Detailed description

Based on the clinical benefits provided by doxorubicin liposome, apatinib and camrelizumab treatment in STS, this study intends to explore the efficacy and safety of doxorubicin liposome hydrochloride and apatinib combined with camrelizumab in the first-line treatment of advanced/unresectable dedifferentiated liposarcoma with the aim of providing a better therapeutic option for the clinic.

Conditions

• Dedifferentiated Liposarcoma
• Soft Tissue Sarcoma (STS)

Interventions

Type	Name	Description
DRUG	Liposomal Doxorubicin (Doxil)	30 mg/m2, d1, IV
DRUG	Apatinib	250 mg, qd
DRUG	Camrelizumab	200 mg, d1, IV

Timeline

• Start date: 2024-12-01
• Primary completion: 2026-06-01
• Completion: 2026-12-01
• First posted: 2024-11-19
• Last updated: 2024-11-19

Locations

1 site across 1 country: China